412 related articles for article (PubMed ID: 32324953)
1. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis.
Pinheiro F; Varejão N; Esperante S; Santos J; Velázquez-Campoy A; Reverter D; Pallarès I; Ventura S
FEBS J; 2021 Jan; 288(1):310-324. PubMed ID: 32324953
[TBL] [Abstract][Full Text] [Related]
2. Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer.
Cotrina EY; Oliveira Â; Leite JP; Llop J; Gales L; Quintana J; Cardoso I; Arsequell G
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998442
[TBL] [Abstract][Full Text] [Related]
3. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
[TBL] [Abstract][Full Text] [Related]
4. Uncovering the Mechanism of Aggregation of Human Transthyretin.
Saelices L; Johnson LM; Liang WY; Sawaya MR; Cascio D; Ruchala P; Whitelegge J; Jiang L; Riek R; Eisenberg DS
J Biol Chem; 2015 Nov; 290(48):28932-43. PubMed ID: 26459562
[TBL] [Abstract][Full Text] [Related]
5. Transthyretin stabilization activity of the catechol-
Gamez J; Salvadó M; Reig N; Suñé P; Casasnovas C; Rojas-Garcia R; Insa R
Amyloid; 2019 Jun; 26(2):74-84. PubMed ID: 31119947
[No Abstract] [Full Text] [Related]
6. Disease-associated mutations impacting BC-loop flexibility trigger long-range transthyretin tetramer destabilization and aggregation.
Esperante SA; Varejāo N; Pinheiro F; Sant'Anna R; Luque-Ortega JR; Alfonso C; Sora V; Papaleo E; Rivas G; Reverter D; Ventura S
J Biol Chem; 2021 Sep; 297(3):101039. PubMed ID: 34343569
[TBL] [Abstract][Full Text] [Related]
7. Dissecting the structure, thermodynamic stability, and aggregation properties of the A25T transthyretin (A25T-TTR) variant involved in leptomeningeal amyloidosis: identifying protein partners that co-aggregate during A25T-TTR fibrillogenesis in cerebrospinal fluid.
Azevedo EP; Pereira HM; Garratt RC; Kelly JW; Foguel D; Palhano FL
Biochemistry; 2011 Dec; 50(51):11070-83. PubMed ID: 22091638
[TBL] [Abstract][Full Text] [Related]
8. The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses.
Sant'Anna R; Braga C; Varejão N; Pimenta KM; Graña-Montes R; Alves A; Cortines J; Cordeiro Y; Ventura S; Foguel D
J Biol Chem; 2014 Oct; 289(41):28324-37. PubMed ID: 25086037
[TBL] [Abstract][Full Text] [Related]
9. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity.
Sant'Anna R; Gallego P; Robinson LZ; Pereira-Henriques A; Ferreira N; Pinheiro F; Esperante S; Pallares I; Huertas O; Almeida MR; Reixach N; Insa R; Velazquez-Campoy A; Reverter D; Reig N; Ventura S
Nat Commun; 2016 Feb; 7():10787. PubMed ID: 26902880
[TBL] [Abstract][Full Text] [Related]
10. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
11. Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis.
Ferreira N; Saraiva MJ; Almeida MR
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875761
[TBL] [Abstract][Full Text] [Related]
12. Development of a Highly Potent Transthyretin Amyloidogenesis Inhibitor: Design, Synthesis, and Evaluation.
Pinheiro F; Pallarès I; Peccati F; Sánchez-Morales A; Varejão N; Bezerra F; Ortega-Alarcon D; Gonzalez D; Osorio M; Navarro S; Velázquez-Campoy A; Almeida MR; Reverter D; Busqué F; Alibés R; Sodupe M; Ventura S
J Med Chem; 2022 Nov; 65(21):14673-14691. PubMed ID: 36306808
[TBL] [Abstract][Full Text] [Related]
13. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology.
Sekijima Y; Hammarström P; Matsumura M; Shimizu Y; Iwata M; Tokuda T; Ikeda S; Kelly JW
Lab Invest; 2003 Mar; 83(3):409-17. PubMed ID: 12649341
[TBL] [Abstract][Full Text] [Related]
14. Disulfide-bond formation in the transthyretin mutant Y114C prevents amyloid fibril formation in vivo and in vitro.
Eneqvist T; Olofsson A; Ando Y; Miyakawa T; Katsuragi S; Jass J; Lundgren E; Sauer-Eriksson AE
Biochemistry; 2002 Nov; 41(44):13143-51. PubMed ID: 12403615
[TBL] [Abstract][Full Text] [Related]
15. Monoaryl derivatives as transthyretin fibril formation inhibitors: Design, synthesis, biological evaluation and structural analysis.
Ciccone L; Nencetti S; Tonali N; Fruchart-Gaillard C; Shepard W; Nuti E; Camodeca C; Rossello A; Orlandini E
Bioorg Med Chem; 2020 Sep; 28(18):115673. PubMed ID: 32828431
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
[TBL] [Abstract][Full Text] [Related]
17. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?
Hammarström P; Sekijima Y; White JT; Wiseman RL; Lim A; Costello CE; Altland K; Garzuly F; Budka H; Kelly JW
Biochemistry; 2003 Jun; 42(22):6656-63. PubMed ID: 12779320
[TBL] [Abstract][Full Text] [Related]
18. Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation.
Sant'Anna R; Almeida MR; Varejāo N; Gallego P; Esperante S; Ferreira P; Pereira-Henriques A; Palhano FL; de Carvalho M; Foguel D; Reverter D; Saraiva MJ; Ventura S
Sci Rep; 2017 Mar; 7():44709. PubMed ID: 28338000
[TBL] [Abstract][Full Text] [Related]
19. Quantification of quaternary structure stability in aggregation-prone proteins under physiological conditions: the transthyretin case.
Robinson LZ; Reixach N
Biochemistry; 2014 Oct; 53(41):6496-510. PubMed ID: 25245430
[TBL] [Abstract][Full Text] [Related]
20. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis.
Liang Y; Ore MO; Morin S; Wilson DJ
Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
